Janet Stewart is a life sciences writer and editor, who completed both PhD course work and oral examinations in the Department of Microbiology and Immunology at McGill University, and holds an M.Sc. in Virology and Immunology.
A combination of Venclexta (venetoclax) plus Rituxan (rituximab) was better than standard of care at extending the duration of undetectable residual ... Read more
Seattle Genetics reported promising five-year survival results from its Phase 1 clinical trial of Adcetris (brentuximab vedotin) in mature T-cell lymphoma ... Read more
A new 3D imaging approach for patients with early-stage Hodgkin lymphoma (HL) was better at predicting survival outcomes than standard two-dimensional ... Read more
The U.S. Food and Drug Administration (FDA) has approved Seattle Genetics’ Adcetris (brentuximab vedotin) for the treatment of adults with the ... Read more
Bayer will present long-term safety and efficacy data from the CHRONOS-1 trial of Aliqopa (copanlisib) in patients with indolent lymphomas at ... Read more
Janssen‘s Imbruvica (ibrutinib) has been approved by Health Canada for treating chronic graft-versus-host disease (cGVHD), a life-threatening condition that some patients ... Read more
Topical remetinostat 1% gel can significantly reduce the severity of skin lesions and itching in mycosis fungoides (MF) patients without systemic adverse ... Read more
More than half of patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL, a particularly aggressive type of lymphoma) ... Read more
